CV Therapeutics' Ranexa is expected to fall well short of Wall Street expectations. Given the growing popularity of invasive angina techniques and the drug's relatively unimpressive trial results, CV Therapeutics' Ranexa looks set to disappoint Wall Street expectations. Datamonitor forecasts Ranexa to generate US revenues of around $20 million in 2006, rising to $163 million by 2009, well below Wall Street consensus of $33 million and $313 million, respectively. Pharmaceutical Business Review (http://www.pharmaceutical-business-review.com/article_feature.asp?guid=C05FBF43-187F-4529-B66D-9F738844B3EF)
Simplifying Global Compliance
Recommended Products
EU MDR Compliance: A Checklist for Meeting Manufacturing, Safety and Performance Requirements
The FDAnews report EU MDR Compliance can help. Our editors have combed through the regulations, picking out the most minute compliance points and building them into a checklist of 200+ requirements you can use to confirm that you are satisfying all the EU mandates for device manufacturing.
Accelerating Generic Drug Development: The FDA’s New Plan for Increasing Generic Competition
Accelerating Generic Drug Development explains the FDA’s new policy and shows how to navigate the new pathway to approval.
Editor's Picks
FDA Seeks Input on Risk-Benefit Reviews for Weight Loss Devices
The FDA said it “continues to receive a high volume of pre-submissions from industry requesting feedback about the necessary data to support pivotal clinical studies and marketing applications for a wide variety of device designs intended for weight loss.”
Costa Rican OTC Drugmaker Hit for Testing, Stability Program
The company said it would employ a third-party testing laboratory, but it didn’t provide a description of the test it would conduct.
